Possible scenario
Regulatory Clarity
20% Chance
The next phase of Moderna's story turns on regulatory execution and data durability. Investors focus on labeling, manufacturing readiness, post-approval surveillance, and the path for the Moderna-Merck melanoma program.
Secondary impacts
- Healthcare +0.1%
Tickers
- MRK+0.7%
- MRNA-0.2%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.